Irish Association for Cancer Research Meeting, Belfast (March 2012)

Angiotox Co-ordinator Dr. Annette Byrne delivered a lecture at the 'Angiogenesis & Inflammation' session, entitled 'Mechanisms of Toxicity associated with Clinically Approved Angiogenisis Inhibitors'

Dr. Rhys Evans also presented a poster at the 'Oral Poster Presentations'

14th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions conference in La Jolla, San Diego, California (February 2012)

Dr. Rhys Evans (Pictured below right) recently presented a poster at this conference entitled 'Cardiovascular Toxicities associated with the Receptor Tyrosine Kinase Inhibitor Sunitinib:

A Multi-Modality Molecular Imaging (MMI) approach' . Dr Evan's poster received a high level of interest from meeting participants and presenters alike. In

Dr. Rhys Evans

particular several attendees commented on the successful Angiotox approach towards ' reverse translation' of clinical toxicity findings as manifested by prolonged increases in blood pressure observed in animal models. The MMI approach taken was further commended as a convincing approach towards the early detection of angiogenesis inhibitor toxicities.

AngioTox Fellow Chosen to Participate in EuroBioimaging Iniative (January 2012)

Dr Alice O'Farrell (AngioTox Marie Curie Fellow, RCSI) has recently been successful in an application to participate in the EuroBioimaging (www.eurobioimaging.eu) proof-of-concept initiative. The EuroBioimaging training initiative is a competitive, peer reviewed platform to provide unique training to Fellows and trainees in the molecular imaging space. Dr O'Farrell's application was chosen from more than two hundred submitted proposals across Europe. The 8 week secondment is to take place at the National PET centre in Turku, Finland later in 2012. Currently at the Royal College of Surgeons, the effect of treatment with angiogenesis inhibitors on cardiac function is being investigated using novel radioisotope imaging strategies. The work that is proposed for the course of the study period will greatly enhance ongoing investigations and will further interrogate novel PET and MR imaging approaches for predictive value in identifying subjects at risk of cardiotoxicity following angiogenesis inhibitor treatment. In addition, Dr O'Farrell will have the opportunity to work with experts in the Cardiotoxicity field and gain valuable knowledge and hands-on experience of state of the art non-invasive imaging methods.

New collaboration formed with Nuclear Imaging Department of Universite de Sherbrooke.

RCSI and UCD have begun a collaboration with the laboratory of imaging expert Professor Roger Lecomte to investigate cardiovascular toxicities associated with angiogenesis inhibitors using novel and established PET tracers.

AngioTox first year meeting takes place at VUMC (September 2011)

Representatives from each of the consortium members were present at the year one meeting to discuss the results obtained from the previous years work and establish what would occur over the next 12 months.

 AngioTox employee presents at Marie Curie conference in Warsaw (September 2011)

AngioTox was represented at the recent Marie Curie conference as Rhys Evans presented a poster titled: Mechanistic Assessment of Cardiovascular Toxicities Associated with the Multi-targeted Tyrosine Kinase Inhibitor Sunitinib. This detailed results obtained from previous imaging studies and the collaboration with the Professor Roger Lecomte group.